Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  NuVasive, Inc.    NUVA

NUVASIVE, INC.

(NUVA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/14/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
79.29(c) 78.65(c) 79.4(c) 78.97(c) 75.16(c) Last
290 304 634 392 576 036 373 732 2 390 752 Volume
+0.93% -0.81% +0.95% -0.54% -4.82% Change
More quotes
Financials (USD)
Sales 2020 1 229 M
EBIT 2020 197 M
Net income 2020 69,9 M
Debt 2020 312 M
Yield 2020 -
Sales 2021 1 303 M
EBIT 2021 218 M
Net income 2021 94,0 M
Debt 2021 212 M
Yield 2021 -
P/E ratio 2020 55,8x
P/E ratio 2021 41,0x
EV / Sales2020 3,44x
EV / Sales2021 3,17x
Capitalization 3 920 M
More Financials
Company
Nuvasive, Inc. is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal... 
More about the company
Surperformance© ratings of NuVasive, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on NUVASIVE, INC.
02/20NUVASIVE : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
02/20NUVASIVE : 4Q Earnings Snapshot
AQ
02/20NUVASIVE INC : Results of Operations and Financial Condition, Regulation FD Disc..
AQ
02/20NUVASIVE : Announces Fourth Quarter and Full Year 2019 Financial Results
PR
02/13NUVASIVE : Results Validating the Versatility of NuVasive's MaXcess® Retractor i..
PR
02/04NUVASIVE : Announces Conference Call and Webcast of Fourth Quarter and Full Year..
PR
01/13NUVASIVE INC : Results of Operations and Financial Condition (form 8-K)
AQ
01/13NUVASIVE : Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Rev..
PR
01/06NUVASIVE : to Participate in 38th Annual J.P. Morgan Healthcare Conference
PR
01/02NUVASIVE INC : Change in Directors or Principal Officers, Regulation FD Disclosu..
AQ
01/02NUVASIVE : Appoints Matthew K. Harbaugh as Chief Financial Officer
PR
2019NUVASIVE : to Present at the 31st Annual Piper Jaffray Healthcare Conference
PR
2019NUVASIVE : Receives FDA Clearance for Expanded Multi-Level Use of CoRoent Small ..
PR
2019NUVASIVE : to Participate as Double Diamond Sponsor at the 13th International Co..
PR
2019NUVASIVE : to Participate as Gold Sponsor at the Cervical Spine Research Society..
PR
More news
News in other languages on NUVASIVE, INC.
2019L'Europe finit en nette hausse, espoir sur le commerce et les banques
2019STOCK MARKET PARIS : Les valeurs à suivre à Paris et en Europe (actualisé)
2019PROTHÈSES : Smith&Nephew veut racheter l'américain NuVasive
2014NUVASIVE, INC. : publication des résultats trimestriels
2013NuVasive(R) baut sein Führungsteam in Europa weiter aus
More news
Analyst Recommendations on NUVASIVE, INC.
More recommendations
Sector news : Medical Equipment, Supplies & Distribution - NEC
11:41aPharmaceutical companies develop system to better track counterfeit drugs
RE
02/20FISHER & PAYKEL HEALTHCARE : F&P Healthcare Raises Fiscal Year Earnings, Revenue..
DJ
02/20SMITH & NEPHEW : +Nephew forecasts sales growth after best year since 2010
RE
02/18MEDTRONIC : Raises 2020 Guidance, Sets 4Q Outlook
DJ
02/18MEDTRONIC : 3Q Profit, Sales Rise
DJ
More sector news : Medical Equipment, Supplies & Distribution - NEC
Chart NUVASIVE, INC.
Duration : Period :
NuVasive, Inc. Technical Analysis Chart | NUVA | US6707041058 | MarketScreener
Technical analysis trends NUVASIVE, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 81,75  $
Last Close Price 75,16  $
Spread / Highest target 23,7%
Spread / Average Target 8,77%
Spread / Lowest Target -25,5%
EPS Revisions
Managers
NameTitle
J. Christopher Barry Chief Executive Officer & Director
Matthew W. Link President
Dale Wolf Senior Vice President-Global Operations
Matthew K. Harbaugh Chief Financial Officer & Executive Vice President
Kyle Malone Senior Director-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
NUVASIVE, INC.-2.82%4 112
MEDTRONIC PLC0.28%152 662
BAXTER INTERNATIONAL INC.11.29%47 512
HOYA CORPORATION-0.10%34 262
ZIMMER BIOMET HOLDINGS5.82%32 578
DEXCOM, INC.38.30%27 708